CytomX Therapeutics (NASDAQ: CTMX) reported Q3 EPS of ($0.35), $0.02 worse than the analyst estimate of ($0.33). Revenue for the quarter came in at $16.92 million versus the consensus estimate of $18.27 million.

For earnings history and earnings-related data on CytomX Therapeutics (CTMX) click here.